Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results

作者：Iben Spanggaard, Marc Matrana, Caio Rocha Lima, Amit Mahipal, María Vieito, Alice Hervieu, Lipika Goyal, Jordi Rodón, Maria Luisa Veronese, Natália Cristina de Oliveira, Xin Li, Michael Schäffer, Santosh Kesari · 发表于：The Oncologist · 年份：2025 · DOI：10.1093/oncolo/oyaf272 · 被引用次数：2 · 研究领域：Fibroblast Growth Factor Research、Cancer, Hypoxia, and Metabolism、Microtubule and mitosis dynamics

Central nervous system (CNS) tumors often harbor alterations in genes regulating key cellular pathways, including fibroblast growth factor receptor (FGFR) genes. Here, we report the efficacy and safety of treatment with pemigatinib, an oral, potent, selective FGFR1-3 inhibitor, in patients with advanced FGFR-altered CNS tumors. FIGHT-207 was a single-arm, open-label, phase 2 study of pemigatinib in patients with advanced solid tumors harboring FGFR fusions/rearrangements or other mutations. Patients received pemigatinib 13.5 mg once daily until disease progression or unacceptable toxicity. Endpoints included tumor response and safety. Of the 13 patients with CNS tumors in FIGHT-207, 10 had glioblastoma. Fibroblast growth factor receptor alterations were FGFR3-TACC3 fusions (n = 9), FGFR1 K656E mutations (n = 2), FGFR1 N546K mutation (n = 1), and FGFR1-MITF fusion (n = 1). Three patients (23%) displayed objective responses (1 complete, 2 partial). Safety was consistent with the overall FIGHT-207 population. Pemigatinib had antitumor activity and a manageable safety profile in patients with CNS tumors.